Original articleAutophagy as a potential therapeutic target during epithelial to mesenchymal transition in renal cell carcinoma: An in vitro study
Introduction
Renal cell carcinoma (RCC) is the most common and aggressive renal neoplasia. RCC is potentially curable by surgical excision if diagnosed early; however, it becomes virtually incurable on metastasis to distant sites. Amongst the various subtypes of RCC, clear cell renal cell carcinoma (CCRCC) is the most prevalent form and constitutes 70–80% of all renal cancers [1].
Epithelial to mesenchymal transition (EMT) is a crucial process regulating the initial steps of metastatic progression. Therefore, key regulatory mechanisms and mediators of EMT may provide the new paradigms to develop novel therapeutics with broad clinical applicability. In RCC, it has been demonstrated that there is acquisition of EMT-like characteristics during the malignant transformation of renal epithelial cells [2], [3]. A recent study have considered and evaluated expression of EMT linked genes as a prognostic factor in the RCC [4]. EMT may lead to cancer cell invasion, metastasis, and drug resistance [5]. It has been reported earlier that anti-cancer therapies, including cytotoxic chemotherapy and pathway inhibitors can induce autophagy in most cancer cell lines [6]. Besides metabolic or cell intrinsic stresses, therapy-induced autophagy can limit the antitumor efficacy of a number of therapies [7]. Although autophagy can exert negative effects on tumor formation and progression, it has also been observed to support tumor survival and progression in many cases [8]. There exists a complex relation between autophagy, EMT and metastasis. Cells undergoing EMT require autophagy activation for survival during the metastatic spreading, on the other hand, autophagy acts as oncosuppressive signal to inhibit the early metastasis. During EMT, cancer cells go through morphological reprogramming and reorganisation of the cytoskeleton and promote autophagy for viability of potentially metastatic cancer cells [9], [10]. The activation of autophagic machinery has also been shown to cause reversion of the EMT phenotype [11], [12], [13], [14], [15]. Various evidences suggest that autophagy can control EMT through selective degradation of EMT proteins [16], [17]. In view of the dual role of autophagy in tumor progression, it is important to test its role in context dependent manner. It has been reported that the serine- threonine kinase, mTOR facilitates cell proliferation in presence of nutrients and growth factors while suppressing autophagy [18]. Pharmacologic inhibition of mTOR has been shown to supress tumor growth in both preclinical models and in patients with RCC. mTOR inhibitors (temsirolimus and evorilimus) have demonstrated a significant clinical activity in patients of advanced RCC [19], [20], [21] however the improvement in overall survival is not statistically significant [22], [23]. The duration of response is often limited and after sometime tumor cells become refractory to treatment and resistance develops in majority of patients [24]. Since mTOR inhibitors are known to induce autophagy therefore autophagy can be considered as a mechanism for tumor cells to escape therapy induced cell death and hence compromise efficacy of mTOR inhibitors in RCC.
In the present study, we identified autophagy as a potential mechanism of cell survival in metastatic RCC cells in vitro thus implying that autophagy inhibition can lead to enhanced cell death. We also observed that tumor cells especially EMT transformed cells, have been ‘primed’ to undergo autophagy by mTOR inhibition. It was our hypothesis that combined use of autophagy inhibitor and temsirolimus (TEM) would result in improved antitumor activity against RCC in EMT transformed metastatic cells. One of the approaches for inhibiting autophagy is the use of lysosomotropic anti-malarial drug, chloroquine (CQ) so we explore the therapeutic potential of combination of CQ and the mTOR inhibitor, TEM. EMT transformed cells showed increased cell death when autophagy was impaired by addition CQ with TEM. This led us to conclude that modulation of autophagy with the current therapeutic regimen could be useful in targeting the EMT transformed cells along with the bulk tumor cells in RCC.
Section snippets
Cell culture
In-vitro studies were done with A498 cell line procured from National Centre for Cell Sciences (NCCS), Pune India. The cells were further cultured in Dulbecco’s modified eagle’s medium-high glucose (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) and with antibiotics (penicillin- streptomycin,1U/ml) at 37 °C at 5% CO2 in humidified incubator.
EMT induction in cell line
The A498cells were seeded in 6-well culture plates cells and treated with TGF- β (5 ng/ml) for 48 h. TGF-β treated cells were considered as EMT
EMT-like morphological change with TGF- β
A498 cells treated with TGF-β (TGF-β+ve) showed typical elongated, spindle shaped appearance characteristic of mesenchymal phenotype. The untreated cells (TGF-β-ve) retained the epithelial cobble stone appearance thus indicating induction of EMT in TGF-β+ve cells (Fig. 1).
Effect of mTOR inhibitor in RCC
mTOR inhibitor is the standard treatment regimen for RCC patients with metastases, but the response rate is variable. MTT assay showed that significant number of viable cells was found after treatment with 10 μM TEM (Fig. 2
Discussion
The mTOR inhibitors, temsirolimus and everolimus, are clinically approved for treatment of advanced RCC but their effect is not durable and majority of patients eventually experience disease progression while on treatment [24], [25], [26]. It is clear from the previous studies that proportion of EMT cells is higher in metastatic tumor and as evident from our result, mTOR inhibitors do not specifically target the EMT cells. The short-lived clinical response to mTOR inhibitors suggest that the
Acknowledgements
Authors acknowledge the technical staff of the Central sophisticated Instrumention Centre of PGIMER. Ms Mamta Singla received senior research fellowship from Indian Council of Medical Research (ICMR) Govt. of India.
References (47)
- et al.
Expression of snail and slug in renal cell carcinoma: E-cadherin repressor snail is associated with cancer invasion and prognosis
Lab. Invest.
(2011) - et al.
Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma
J. Urol.
(2014) - et al.
Autophagy induction impairs migration and invasion by reversing EMT in glioblastoma cells
Mol. Oncol.
(2015) - et al.
Autophagy links beta-catenin and Smad signaling to promote epithelial-mesenchymal transition via upregulation of integrin linked kinase
Int. J. Biochem. Cell Biol.
(2016) - et al.
mTOR regulation of autophagy
FEBS Lett.
(2010) - et al.
mTOR inhibitors in advanced renal cell carcinoma
Hematol. Oncol. Clin. North Am.
(2011) - et al.
Autophagy and metastasis: another double-edged sword
Curr. Opin. Cell Biol.
(2010) - et al.
Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis
Dev. Cell
(2008) - et al.
VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3 B-mediated autophagy in renal clear cell carcinoma
Cancer Cell.
(2012) - et al.
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy
Cancer Cell.
(2008)
Activation of the mTOR signaling pathway in renal cell carcinoma
J. Urol.
Epidemiology and risk factors for kidney cancer
Nat. Rev. Urol.
The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma
PLoS One
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis
Cancer Res.
The roles of therapy-induced autophagy and necrosis in cancer treatment
Clin. Cancer Res.
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma
Clin. Cancer Res.
Principles and current strategies for targeting autophagy for cancer treatment
Clin. Cancer Res.
Induction of autophagy during extracellular matrix detachment promotes cell survival
Mol. Biol. Cell
Autophagic targeting of Src promotes cancer cell survival following reduced FAK signalling
Nat. Cell Bio.
DEDD interacts with PI3KC3 to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer
Cancer Res.
Regulation of cell proliferation and migration by p62 through stabilization of Twist1
Proc. Natl. Acad. Sci. U. S. A.
Enhanced epithelial-to-mesenchymal transition associated with lysosome dysfunction in podocytes: role of p62/Sequestosome 1 as a signaling hub
Cell. Physiol. Biochem.
Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy
Oncogene
Cited by (60)
Metastatic outgrowth via the two-way interplay of autophagy and metabolism
2024, Biochimica et Biophysica Acta - Molecular Basis of DiseaseEnhancers of mesenchymal stem cell stemness and therapeutic potency
2023, Biomedicine and PharmacotherapyAutophagy and EMT in cancer and metastasis: Who controls whom?
2022, Biochimica et Biophysica Acta - Molecular Basis of Disease